iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches
Advanced Drug Delivery Reviews · 2025-12 · 227 · 115713
DOI: 10.1016/j.addr.2025.115713 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2025-12. Verfasst von Débora Basílio-Queirós und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Macrophages, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon Europe, Deutsche Forschungsgemeinschaft, Deutsches Zentrum für Lungenforschung.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) technology has transformed the immunotherapy field with significant success in the treatment of hematological diseases. Nonetheless, challenges in scalability, donor variability as well as in the treatment of solid tumors warrants innovative solutions. Induced pluripotent stem cell (iPSC) technology has revolutionized the filed as an emerging renewable source for CAR-based therapies, facilitating the development of off-the-shelf immune cells products. This review focuses on the recent developments of iPSC-derived CAR-T cells and CAR-macrophages, including differentiation protocols, gene engineering strategies and mitigation of Graft-versus-Host Disease (GvHD), as well as alternatives for histocompatibility constraints. Additionally, we will discuss how iPSC-derivation enhances accessibility of low-frequency immune cell populations including MR1-restricted αβT, γδT, Natural Killer T (NKT) and Microglial cells. Despite great progress achieved, the limited but continuously growing clinical experience and manufacturing challenges, warrant further exploration. Advancements in manufacturing scalability and genetic engineering position iPSC-based therapies at the forefront of clinical strategies to address unmet clinical needs in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
- Cell Therapy Sciences, Takeda, Cambridge, MA, USA.
- Chan Zuckerberg Biohub New York, New York, USA.
- Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany; REBIRTH, Research Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germa…
Förderung
- Horizon Europe
- Deutsche Forschungsgemeinschaft
- Deutsches Zentrum für Lungenforschung
- European Research Council
- Horizon 2020 Framework Programme
- Bundesministerium für Forschung, Technologie und Raumfahrt
- European Commission
- REBIRTH HANNOVER Forschungszentrum für translationale regenerative Medizin
Zitieren
APA
Basílio-Queirós, D., Rivière, I., van der Stegen, S. J. C., & Lachmann, N. (2025). iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches. Advanced Drug Delivery Reviews, 227, 115713. https://doi.org/10.1016/j.addr.2025.115713
Vancouver
Basílio-Queirós D, Rivière I, van der Stegen SJC, Lachmann N. iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches. Advanced Drug Delivery Reviews. 2025;227:115713. doi:10.1016/j.addr.2025.115713
BibTeX
@article{BaslioQueirs2025,
author = {Basílio-Queirós, Débora and Rivière, Isabelle and van der Stegen, Sjoukje J C and Lachmann, Nico},
title = {iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches},
journal = {Advanced Drug Delivery Reviews},
year = {2025},
volume = {227},
pages = {115713},
doi = {10.1016/j.addr.2025.115713}
}
EUVIMED